| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en)* | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| PT92900A (en)* | 1989-01-24 | 1990-07-31 | | EXPRESSION VECTOR SYSTEM FOR THE PRODUCTION OF QUIMERIC MONOCLONAL ANTIBODIES |
| FR2649488A1 (en)* | 1989-07-07 | 1991-01-11 | Inst Nat Sante Rech Med | FRAGMENTS OF MONOCLONAL ANTIBODIES SPECIFIC TO THE PRESENCE OF ACTIVE LEUKOCYTES - THEIR PROCESS FOR OBTAINING AND THEIR APPLICATION IN THE CASE OF A GRAFT REJECT |
| ATE236249T1 (en) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | TFN-BINDING PROTEINS |
| US5196320A (en)* | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
| FR2652746A1 (en)* | 1989-10-06 | 1991-04-12 | Merieux Inst | APPLICATION OF ACTIVE AGENTS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF LYMPHOMA OR THE LIKE. |
| FR2652747B1 (en)* | 1989-10-06 | 1995-03-31 | Merieux Inst | APPLICATION OF ACTIVE AGENTS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AUTOIMMUNE DISEASES. |
| GR1001050B (en)* | 1990-01-09 | 1993-04-28 | Protein Design Labs Inc | Particular human immunoglobulin receiver of il-2 new type |
| HUT60768A (en)* | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| DE4018442A1 (en)* | 1990-06-08 | 1991-12-12 | Boehringer Mannheim Gmbh | RECOMBINANT DNA AND METHOD FOR PRODUCING CHIMERIC ANTIBODIES |
| DE4028955A1 (en) | 1990-09-12 | 1992-03-19 | Boehringer Mannheim Gmbh | MONOCLONAL ANTIBODIES AGAINST THE INTERLEUKIN 2 RECEPTOR |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en)* | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5621083A (en)* | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5837491A (en)* | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| DE69233204T2 (en)* | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
| US5869619A (en)* | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE19543039C1 (en)* | 1995-11-08 | 1996-11-21 | Medac Klinische Spezialpraep | DNA mols. encoding CD30-specific immunoglobulin variable regions |
| WO1997028828A1 (en) | 1996-02-09 | 1997-08-14 | Amgen Boulder Inc. | Composition comprising interleukin-1 inhibitor and controlled release polymer |
| US6013256A (en)* | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| JP4771563B2 (en) | 1996-12-06 | 2011-09-14 | アムジエン・インコーポレーテツド | Combination therapy using IL-1 inhibitors to treat IL-1 mediated diseases |
| DE69833755T2 (en) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS |
| ES2291040T3 (en)* | 1998-07-27 | 2008-02-16 | Novartis Ag | USE OF BASILIXIMAB IN THE TREATMENT OF REUMATOID ARTHRITIS OR SKIN DISEASES. |
| CA2373815A1 (en) | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| ATE497171T1 (en) | 1999-07-05 | 2011-02-15 | Leuven K U Res & Dev | VON WILLEBRAND FACTOR ACTIVITY PROOF |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US7071319B2 (en) | 2000-05-16 | 2006-07-04 | Thomas Jefferson University | Recombinant antibodies, and compositions and methods for making and using the same |
| DE60136174D1 (en) | 2000-05-16 | 2008-11-27 | Univ Jefferson | RABIESVIRUS-SPECIFIC NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AND NUCLEIC ACIDS AND RELATED METHODS |
| ATE400030T1 (en) | 2001-02-19 | 2008-07-15 | Merck Patent Gmbh | METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY |
| WO2004002500A1 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| ES2534294T3 (en) | 2002-07-19 | 2015-04-21 | Beth Israel Deaconess Medical Center | Methods to treat preeclampsia |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| JP2007531505A (en) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | Techniques and compositions for diagnosis and treatment of cancer (MUC1) |
| CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| BRPI0416141B8 (en) | 2003-11-01 | 2021-05-25 | Biovation Ltd | modified anti-cd52 antibody, pharmaceutical composition, expression vectors, and method of preparing an immunoglobulin |
| ATE426617T1 (en) | 2003-12-05 | 2009-04-15 | Multimmune Gmbh | THERAPEUTIC AND DIAGNOSTIC ANTI-HSP 70- ANTIBODIES |
| DK1735348T3 (en) | 2004-03-19 | 2012-07-16 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US8492106B2 (en) | 2004-05-24 | 2013-07-23 | Universitat Zu Koln | Identification methods for ergothioneine transporter modulators and therapeutic uses thereof |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| WO2006021893A2 (en) | 2004-08-26 | 2006-03-02 | The University Of Western Ontario | Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus |
| AU2005286626B2 (en) | 2004-09-24 | 2012-11-08 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating complications of pregnancy |
| SI1797127T1 (en) | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modified fc molecules |
| DK1819358T3 (en) | 2004-11-18 | 2014-10-27 | Imclone Llc | Antibodies to Vascular Endothelial Growth Factor Receptor-1 |
| WO2006083355A2 (en) | 2004-11-19 | 2006-08-10 | Cornell Research Foundation, Inc. | Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| ES2720288T3 (en) | 2005-03-30 | 2019-07-19 | Minerva Biotechnologies Corp | Proliferation of cells expressing MUC1 |
| WO2006105448A2 (en) | 2005-03-30 | 2006-10-05 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| EP1712557A1 (en) | 2005-04-14 | 2006-10-18 | RWTH Aachen | New s-adenosyl-L-methionine analogues with extended activated groups for transfer by methyltransferases |
| CN101612399B (en) | 2005-06-17 | 2013-11-27 | 英克隆有限责任公司 | Anti-PDGFRα antibody for use in the treatment of secondary bone tumors |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| JP5164167B2 (en) | 2005-08-30 | 2013-03-13 | ユニバーシティー オブ マイアミ | Agonists, antagonists and immunotoxins of immunoregulatory tumor necrosis factor receptor 25 (TNFR25) |
| MY157757A (en) | 2006-07-18 | 2016-07-15 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2668295A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
| KR101735257B1 (en) | 2007-01-05 | 2017-05-12 | 유니버시티 오브 취리히 | Method of providing disease-specific binding molecules and targets |
| US8519106B2 (en) | 2007-03-13 | 2013-08-27 | University Of Zurich | Monoclonal human tumor-specific antibody |
| WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
| KR100883430B1 (en) | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | Human monoclonal antibodies neutralizing vascular endothelial growth factor receptors and uses thereof |
| EP2167528B1 (en) | 2007-06-21 | 2018-01-10 | Angelica Therapeutics, INC. | Modified toxins |
| MX338395B (en) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses. |
| WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2220121B1 (en) | 2007-11-12 | 2015-08-19 | U3 Pharma GmbH | Axl antibodies |
| WO2009114585A1 (en) | 2008-03-12 | 2009-09-17 | Imclone Llc | Anti-tyrp1 antibodies |
| AR071891A1 (en) | 2008-05-30 | 2010-07-21 | Imclone Llc | ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE) |
| CN102282172B (en) | 2008-09-07 | 2014-02-19 | 台湾醣联生技医药股份有限公司 | Anti-stretched type I glycosphingolipid antibody, derivatives and uses thereof |
| KR20200133324A (en) | 2008-10-09 | 2020-11-27 | 미네르바 바이오테크놀로지 코포레이션 | Method for inducing pluripotency in cells |
| CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| US20120164659A1 (en) | 2009-08-05 | 2012-06-28 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
| JP5925678B2 (en) | 2009-08-18 | 2016-05-25 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and compositions for the treatment of proliferative and pathogenic diseases |
| WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
| EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| MX349856B (en) | 2010-01-15 | 2017-08-16 | Kirin Amgen Inc | Antibody formulation and therapeutic regimens. |
| JP5841072B2 (en) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | CD20 antibody and use thereof |
| EP2536432B1 (en) | 2010-02-19 | 2018-08-08 | Cornell University | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| AR080698A1 (en) | 2010-04-01 | 2012-05-02 | Imclone Llc | ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND |
| WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012025636A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
| WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
| SG10201508149TA (en) | 2010-10-01 | 2015-10-29 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| US9346889B2 (en) | 2010-10-18 | 2016-05-24 | Mediapharma S.R.L. | ErbB3 binding antibody |
| WO2012080518A1 (en) | 2010-12-17 | 2012-06-21 | Neurimmune Holding Ag | Human anti-sod1 antibodies |
| WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
| EP2678026B1 (en) | 2011-02-21 | 2016-05-18 | The University of Zurich | Ankyrin g for use in the treatment of neurodegenerative disorders |
| WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| CA2830503A1 (en) | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| DE12722942T1 (en) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS |
| EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
| WO2012177972A1 (en) | 2011-06-23 | 2012-12-27 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
| DE202011103324U1 (en) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutic anti-TIRC7 antibodies for use in immune and other diseases |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| MX391157B (en) | 2011-09-19 | 2025-03-21 | Axon Neuroscience Se | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE. |
| DK3682905T3 (en) | 2011-10-03 | 2022-02-28 | Modernatx Inc | MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USES THEREOF |
| WO2013050540A1 (en) | 2011-10-05 | 2013-04-11 | University Of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
| CN109456932A (en) | 2011-10-17 | 2019-03-12 | 米纳瓦生物技术公司 | Culture medium for stem cells hyperplasia and induction |
| EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
| CN110201187A (en) | 2011-12-16 | 2019-09-06 | 现代泰克斯公司 | Modified nucleosides, nucleotide and nucleic acid compositions |
| WO2013093122A2 (en) | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| AU2013206788B2 (en) | 2011-12-28 | 2017-11-30 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| CN103382223B (en) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | Multi-functional antibody polypeptide aiming at epidermal growth factor receptor (EGFR) cryptic epitope and T cell antigen |
| EP3978030A1 (en) | 2012-04-02 | 2022-04-06 | ModernaTX, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP4148135A1 (en) | 2012-07-05 | 2023-03-15 | The Trustees of the University of Pennsylvania | U1 snrnp regulates gene expression and modulates oncogenicity |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| DE102012020496A1 (en) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample |
| ES2921623T3 (en) | 2012-11-26 | 2022-08-30 | Modernatx Inc | terminally modified RNA |
| EP3792278A3 (en) | 2012-12-21 | 2021-05-26 | Biogen MA Inc. | Human anti-tau antibodies |
| EP3517545A1 (en) | 2012-12-31 | 2019-07-31 | Neurimmune Holding AG | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | Modified toxins |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN107460201A (en) | 2013-05-08 | 2017-12-12 | 科济生物医药（上海）有限公司 | Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3 |
| CN112358548B (en) | 2013-07-03 | 2024-10-25 | 因美诺克股份公司 | Human anti-IFN-alpha antibody, IFN-alpha binding fragment, polynucleotide, composition, kit, application and preparation method |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (en) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polynucleotides encoding low density lipoprotein receptor |
| CN104774264B (en) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | Anti-human proBDNF monoclonal antibodies and its effect in pain |
| EP3126392B1 (en) | 2014-03-31 | 2019-09-11 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
| EP3132053B1 (en) | 2014-04-15 | 2020-09-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Differential diagnosis of eczema and psoriasis |
| AU2015254596B2 (en) | 2014-04-30 | 2020-10-22 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Diagnosis of multiple sclerosis |
| TW201628647A (en) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | anti-IL4-IL13 bispecific antibody |
| CN105315375B (en) | 2014-07-17 | 2021-04-23 | 恺兴生命科技(上海)有限公司 | T lymphocytes targeting CLD18A2 and preparation method and application thereof |
| MX391037B (en) | 2014-07-29 | 2025-03-21 | Neurimmune Holding Ag | HUMAN-DERIVED ANTI-HUNTINGTIN (HTT) ANTIBODIES AND THEIR USES. |
| GB201415349D0 (en) | 2014-08-29 | 2014-10-15 | Univ Leuven Kath | Cofactor analogues for methyltransferases |
| MX2017004213A (en) | 2014-09-30 | 2017-07-19 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody. |
| US20170355755A1 (en) | 2014-11-21 | 2017-12-14 | Yale University | Compositions and methods for modulating salm5 and hvem |
| MA41629A (en) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY |
| JP6726676B2 (en) | 2015-03-16 | 2020-07-22 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | Trispecific binding molecules for treating HBV infection and related conditions |
| EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
| ITUB20155097A1 (en) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Humanized anti-BAG3 antibodies |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| ITUA20162242A1 (en) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | A NEW ANTI-ERBB2 ANTIBODY |
| JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
| US10316037B1 (en) | 2016-11-04 | 2019-06-11 | Yale University | Compounds and methods for treating cancer |
| IT201600111877A1 (en) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2018129284A1 (en) | 2017-01-05 | 2018-07-12 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma) |
| TWI808963B (en) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | Treatment of lupus using humanized anti-cxcr5 antibodies |
| US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| KR20210013013A (en) | 2018-03-09 | 2021-02-03 | 카르스젠 테라퓨틱스 리미티드 | Tumor treatment method and composition |
| EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
| WO2019217450A1 (en) | 2018-05-08 | 2019-11-14 | Rhode Island Hospital | Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2020053808A1 (en) | 2018-09-12 | 2020-03-19 | Georg Dewald | Method of diagnosing vasoregulatory disorders |
| EP3880706A1 (en) | 2018-11-12 | 2021-09-22 | MediaPharma S.r.l. | Bispecific antibodies directed against human 90k and either endosialin or her3 |
| WO2020157122A1 (en) | 2019-01-29 | 2020-08-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Treating the causative agent in adhesiogenesis |
| KR20210126078A (en) | 2019-02-13 | 2021-10-19 | 더 브리검 앤드 우먼즈 하스피털, 인크. | Anti-peripheral lymph node addressin antibodies and uses thereof |
| EP3976181A1 (en) | 2019-05-24 | 2022-04-06 | Sanofi | Methods for treating systemic sclerosis |
| WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
| CA3173981A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
| WO2022189632A1 (en) | 2021-03-12 | 2022-09-15 | Fibrosys S.R.L. | Monoclonal antibodies for the treatment of viral infections |
| EP4455161A1 (en) | 2023-04-24 | 2024-10-30 | ONO Pharmaceutical Co., Ltd. | Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies |